Shares of Pfizer are down after the company announced a forecasted revenue slump in 2024 amid declining demand for the company's Wuhan coronavirus (COVID-19) "vaccine" and other related products.
In a press release entitled "Pfizer Provides Full-Year 2024 Guidance," the company wrote that revenues next year are expected to be between $58.5 billion and $61.5 billion, which is below the $62.9 billion that analysts surveyed by Bloomberg expected.
"It expects annual earnings of $2.05 to $2.25 a share, far below analysts' $3.21 average estimate," reported ZeroHedge about expectations going into next year.
Like Moderna, Pfizer's very existence seems to depend upon COVID lasting forever. The company hopes to rake in $8 billion next year from Comirnaty, its mRNA (modRNA) COVID injection, and its antiviral drug Paxlovid. Pfizer also expects to make $3.1 billion from the sale of Seagen next year.
Pfizer also plans to reclassify about $1 billion in royalty income from other income and deductions into the revenue.
"Pfizer's product portfolio remains strong," declared Pfizer Chairman and CEO Albert Bourla.
"In 2024, Comirnaty and Paxlovid are expected to deliver combined revenues of approximately $8 billion and our remaining portfolio of combined Pfizer and Seagen products is expected to achieve year-over-year operational revenue growth in the range of 8 percent to 10 percent."
"In addition, we expect our cost realignment program to deliver savings of at least $4.0 billion by the end of 2024, which puts us on a path to potentially regain our pre-pandemic operating margins."
(Related: Another thing Pfizer is trying to do to scrape every last penny it can from dangerous drugs and vaccines is to rebrand them as "new-and-improved" drugs for other purposes.)
Year-to-date, Pfizer shares down 44 percent – lowest since 2016
The year 2023 was not all that great for Pfizer, either. Most people had already awoken to the fact that the company's COVID injections are deadly, and demand for the shots was already all but gone at the start of the year.
If it were not for jab mandates and other Big Pharma manipulations, Pfizer would have probably gone bankrupt years ago. But thanks to government corruption, Pfizer was able to buy its way into several years of obscene profits due to lucrative government contracts and drug mandates.
"We are acutely aware that all these uncertainties are making it difficult to project the future revenues of Pfizer – and are also affecting our stock price," Bourla told investors on a recent conference call.
Moderna's share price is also tumbling as the company runs out of deadly drugs to force on the public. Nobody wants what Moderna is offering, and the markets know this. It would seem as though the days of the pharmaceutical-industrial complex are numbered.
"Only another pandemic can turn around the industry," reported Zero Hedge about the matter.
"They want and need another scamdemic," wrote a commenter, adding to the sentiment.
"Since Pfizer is just a DoD (Department of Defense) front, I suppose there will be more missing Pentagon trillions to prop it up," suggested another.
"Pfizer is a gangster pharmaceutical corporation that would already be bankrupted by criminal prosecutions if the North American Banana Republic had a real justice system," said someone else.
"COVID and climate change are two of the greatest frauds in world history," said another.
"I remember when the information given was that you could not vaccinate for a virus, since they change their signatures too often, and that it would take at least ten years to develop one," noted someone else. "They either lied then or they are lying now."
The latest news about Pfizer can be found at Evil.news.
Sources for this article include:
Please contact us for more information.
